Medicine Man Technologies, Inc.

As of December 31, 2023, Medicine Man Technologies, Inc. has 74.05M shares outstanding.

As of December 31, 2023, Medicine Man Technologies, Inc. trades at a trailing price-to-earnings ratio of 30.96. The price-to-sales ratio is 0.24, and the price-to-book ratio stands at -0.51.

As of December 31, 2023, Medicine Man Technologies, Inc. trades at an EV/EBITDA multiple of 8.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 41.98 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medicine Man Technologies, Inc. trades at an EV/FCF ratio of 2.19, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2023, Medicine Man Technologies, Inc. maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 160.84, indicating elevated leverage, while an interest coverage ratio of 0.81 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -10.15, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 23.65, useful for judging operating efficiency across full business cycles. Inventory turnover of 3.99 indicates how many times Medicine Man Technologies, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended December 31, 2023. That works out to an effective tax rate of 179.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended December 31, 2023, Medicine Man Technologies, Inc. posted a gross margin of 44.08, reflecting its pricing power and cost economics. The operating margin of 2.95 and net profit margin of -20.03 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2023. The dividend payout ratio of 19.10 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 47.10, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 12.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medicine Man Technologies, Inc. shareholders.

As of December 31, 2023, Medicine Man Technologies, Inc. has an Altman Z-Score of 0.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.